Human Serum Amyloid A1 (SAA1) Recombinant

<strong>Human Serum Amyloid A1 (SAA1) Recombinant</strong>_x000D_ <strong>Catalog number:</strong> B2016408_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 11 814 Da_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> Recombinant human serum amyloid A1 (SAA1)_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Abouelasrar Salama S, De Bondt M, De Buck M, Berghmans N, Proost P, Oliveira VLS, Amaral FA, Gouwy M, Van Damme J, Struyf S. Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1 Front Immunol. 2020 May 14;11:843._x000D_ 2: Gong J, Wu J, Ikeh M, Tao L, Zhang Y, Bing J, Nobile CJ, Huang G. Antifungal Activity of Mammalian Serum Amyloid A1 against Candida albicans Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01975-19._x000D_ 3: Hahn A, Kny M, Pablo-Tortola C, Todiras M, Willenbrock M, Schmidt S, Schmoeckel K, Jorde I, Nowak M, Jarosch E, Sommer T, Bröker BM, Felix SB, Scheidereit C, Weber-Carstens S, Butter C, Luft FC, Fielitz J. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):103-119._x000D_ 4: Yamada T, Sato J, Okuda Y. Differential affinity of serum amyloid A1 isotypes for high-density lipoprotein Amyloid. 2009 Dec;16(4):196-200._x000D_ 5: Han S, Jin SP, Oh JH, Seo EY, Park CH, Yoon HS, Lee DH, Chung JH. Serum amyloid A1 secreted from UV-irradiated keratinocytes induces matrix metalloproteinase-1 in fibroblasts through toll-like receptor 4 Exp Dermatol. 2016 Jul;25(7):526-31._x000D_ 6: Chen M, Zhou H, Cheng N, Qian F, Ye RD. Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2 Immunobiology. 2014 Dec;219(12):916-23._x000D_ 7: Paret C, Schön Z, Szponar A, Kovacs G. Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome Eur Urol. 2010 May;57(5):859-66._x000D_ 8: Leow KY, Goh WW, Heng CK. Effect of serum amyloid A1 treatment on global gene expression in THP-1-derived macrophages Inflamm Res. 2012 Apr;61(4):391-8._x000D_ 9: Gouwy M, De Buck M, Abouelasrar Salama S, Vandooren J, Knoops S, Pörtner N, Vanbrabant L, Berghmans N, Opdenakker G, Proost P, Van Damme J, Struyf S. Matrix Metalloproteinase-9-Generated COOH-, but Not NH(2)-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity Front Immunol. 2018 Jun 4;9:1081._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/10804822">10: Wada A, Yamada T, Itoh K, Igari J. [No significant influence of serum amyloid A1 genotypes on serum lipids or HDL clearance] Rinsho Byori. 2000 Feb;48(2):174-7.</a>_x000D_ _x000D_ <strong>Products Related to Human Serum Amyloid A1 (SAA1) Recombinant can be found at</strong> <a href="https://moleculardepot.com/product-category/Biofluids/"> Biofluids</a>